Tags

Type your tag names separated by a space and hit enter

[New obesity and metabolic syndrome treatment: rimonabant].
Rev Med Suisse. 2006 Jan 04; 2(47):41-5.RM

Abstract

CBI endocannabinoid system receptors localized in the hypothalamus and the nucleus accumbens are known to regulate hunger. Hyperstimulation of the CBI receptors lead to an increase of food intake, but also to an increase of lipogenesis, decrease of adiponectin and increase of insulin resistance. Rimonabant is the first CBI central and peripheral blocker, tested in international trials (RIO-lipids, RIO-Europe and RIO-North America). Significant results on weight reduction, increased adiponectin and improved metabolic syndrome have been demonstrated. Rimonabant is a new pharmacological therapy and very interesting for tackling obesity and metabolic syndrome.

Authors+Show Affiliations

Service d'enseignement thérapeutique pour maladies chroniques, Département de médecine communautaire HUG, 121 I Geneve 14.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

16465944

Citation

Makoundou, V, and A Golay. "[New Obesity and Metabolic Syndrome Treatment: Rimonabant]." Revue Medicale Suisse, vol. 2, no. 47, 2006, pp. 41-5.
Makoundou V, Golay A. [New obesity and metabolic syndrome treatment: rimonabant]. Rev Med Suisse. 2006;2(47):41-5.
Makoundou, V., & Golay, A. (2006). [New obesity and metabolic syndrome treatment: rimonabant]. Revue Medicale Suisse, 2(47), 41-5.
Makoundou V, Golay A. [New Obesity and Metabolic Syndrome Treatment: Rimonabant]. Rev Med Suisse. 2006 Jan 4;2(47):41-5. PubMed PMID: 16465944.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [New obesity and metabolic syndrome treatment: rimonabant]. AU - Makoundou,V, AU - Golay,A, PY - 2006/2/10/pubmed PY - 2006/3/1/medline PY - 2006/2/10/entrez SP - 41 EP - 5 JF - Revue medicale suisse JO - Rev Med Suisse VL - 2 IS - 47 N2 - CBI endocannabinoid system receptors localized in the hypothalamus and the nucleus accumbens are known to regulate hunger. Hyperstimulation of the CBI receptors lead to an increase of food intake, but also to an increase of lipogenesis, decrease of adiponectin and increase of insulin resistance. Rimonabant is the first CBI central and peripheral blocker, tested in international trials (RIO-lipids, RIO-Europe and RIO-North America). Significant results on weight reduction, increased adiponectin and improved metabolic syndrome have been demonstrated. Rimonabant is a new pharmacological therapy and very interesting for tackling obesity and metabolic syndrome. SN - 1660-9379 UR - https://www.unboundmedicine.com/medline/citation/16465944/[New_obesity_and_metabolic_syndrome_treatment:_rimonabant]_ L2 - http://www.diseaseinfosearch.org/result/9028 DB - PRIME DP - Unbound Medicine ER -